Статья Д.Ф. Кима, А.В. Николаева, Ю.А. Барсукова, С.И. Ткачева, С.С. Гордеева «Комплексное лечение больных плоскоклеточным раком анального канала» («Онкологическая колопроктология» № 4 – 2012) посвящена анализу результатов лечения больных с редкой формой злокачественных новообразований терминальной части желудочно-кишечного тракта: плоскоклеточным раком анального канала. Опубликованные данные представляют собой опыт одного учреждения, накопленный в течение 22 лет (1990–2012) и включающий 157 пациентов. По своей репрезентативности эта группа больных одна из самых больших в России, что само по себе делает представленный материал значимым для отечественной практики исследованием.

Несмотря на редкость заболевания, авторам удалось провести сравнительное исследование, в которое больные были включены проспективно, и хотя группы не были сформированы рандомизированно, они сопоставимы по распространенности опухолевого процесса, а оригинальность предложенных схем лечения делает опубликованные результаты чрезвычайно интересными.

Safety and efficacy of intrarectal 5-fluoruracil in combined treatment of localized rectal cancer was investigated in this article. Our data supports safety, economical efficacy and simplicity of use of this method. It improves sphincter preservation rate in patients with distal rectal cancer, does not increase surgical mortality and morbidity, leads to high tumor regression rate, improves local control and decreases distant failure rate.

In this article we present up-to-date views on rectal cancer imaging. Accurate initial and follow-up staging of rectal cancer is vitally important and provides information essential for treatment decision making, preoperative therapy and surgery planning. Almost worldwide magnetic resonance imaging (MRI) is currently considered as the most advanced staging modality for rectal cancer; however conventional MRI sequences have some diagnostic limits and not always allow to differentiate fibrotic tissue (present either desmoplastic reaction or fibrotic changes due to preoperative radiotherapy) from tumor. On the basis of our own experience and published data we tried to demonstrate imaging possibilities of conventional and diffusion-weighted (DW) MRI in local staging of rectal cancer.

The review literature regarding endovascular interventions for rectal cancer treatment is presented. The results of treatment of loco-regional rectal carcinoma by with the help of endovascular selective lipiodol oil chemoembolization of the rectal arteries, and also the data concerning features of blood supply of rectum, received by selective angiography are presented. The results confirm expediency of endovascular methods in treatment of rectal cancer considering specific features of blood supply of rectum.

Technique and surgical outcomes of anatomical liver resections using ERBEJET2® water-jet dissector were described. Overall 98 patients with colorectal cancer liver metastases were included in this study. In 43 patients resections were performed using water-jet dissection technique. Water-jet dissection seems to be safe and effective technique for anatomical liver resections.

The review literature regarding endovascular interventions for rectal cancer treatment is presented. The results of treatment of loco-regional rectal carcinoma by with the help of endovascular selective lipiodol oil chemoembolization of the rectal arteries, and also the data concerning features of blood supply of rectum, received by selective angiography are presented. The results confirm expediency of endovascular methods in treatment of rectal cancer considering specific features of blood supply of rectum.

The efficiency of 2 programs of chemotherapy in the treatment of 46 patients with disseminated colorectal cancer. The program of chemo-therapy of oxaliplatin + capecitabine (ОХА/САР), established authors, with bevacizumab (BEV) showed the best results compared with oxaliplatin + 5-fluorouracyl + leukovorin (ОХА/5-FU/LV) with bevacizumab. The overall efficiency OXA/5-FU/LV/BEV amounted to 40.91 ± 8.6 %, 4.54 ± 5.1 % of total regressions. The overall effect of therapy in the OXA/CAP/BEV amounted to 45.83 ± 8.6 %, full regression was achieved in 4 patients, which amounted to 16.66 ± 5.6 %. The median time to progression in the first group of patients was 8.3 months, in the second – 9.8 months. Clinical application of involving bevacizumab in combination with different modes of chemotherapy in patients with disseminated colorectal cancer is acceptable and manageable toxicity that doesn't require reduction of doses.

A case report of a patient with advanced colorectal cancer complicated by 18-year immunosuppressive drug therapy after kidney transplantation is presented. Long-term use of immunosuppressive drugs may complicate postoperative period, but must not be a contradiction to extensive abdominal and pelvic surgery.

Avastin in combination with standard chemotherapy (CT) is an effective treatment regimen in 1st and 2nd line metastatic colorectal cancer (mCRC). Data of observational cohort programs and results of a randomized TML trial confirmed the efficacy of Avastin plus CT continued beyond first progression in patients with mCRC previously treated with Avastin plus CT.

Author presents her own experience of prolonged Avastin therapy combined with several serial CT lines in mCRC patient